Trial description:
LI (less intensive)-1 will evaluate several relevent therapeutic questions in Acute Myeloid Leukemia (AML) as defined by the WHO and High-Risk Myelodysplastic Syndrome. The trial is primarily designed for patients ver 60 years for whom conventional chemotherapy is not considered suitable. The trial is part of a continuous program of developement aimed at improving the outcomes of treatment in this patient population
Contact name:
Dr Kiran Tawana
Trial start date:
Monday, February 17, 2014
Trial end date:
Thursday, December 31, 2020
Trial tumour type:
Haematological
Show on Radiotherapy:
No
